Some methodological considerations in the evaluation of drug-induced extrapyramidal disorders: a study of Ex10-029, a new morphanthridine derivative.
D000328:Adult; D000978:Antiparkinson Agents / Q000627:therapeutic use; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000188:drug therapy; D001712:Biperiden / Q000627:therapeutic use; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003514:Cyclohexylamines / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D006236:Handwriting; D006801:Humans; D008297:Male; D008875:Middle Aged; D009019:Morphinans / Q000627:therapeutic use*; D009069:Movement Disorders / Q000139:chemically induced*; D010300:Parkinson Disease / Q000188:drug therapy*; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy*; D013451:Sulfonic Acids / Q000627:therapeutic use; D013997:Time Factors; D014149:Tranquilizing Agents / Q000009:adverse effects* / Q000627:therapeutic use
D000978:Antiparkinson Agents; D003514:Cyclohexylamines; D009019:Morphinans; D013451:Sulfonic Acids; D014149:Tranquilizing Agents; D001712:Biperiden